- Home
- GWRE vs ABVX Comparison
GWRE vs ABVX Comparison
Compare GWRE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GWRE | ABVX |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 9.7B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | GWRE | ABVX |
|---|---|---|
| Price | $138.21 | $106.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $251.31 | $131.31 |
| AVG Volume (30 Days) | ★ 1.2M | 773.7K |
| Earning Date | 06-02-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1257.14 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $719,514,000.00 | N/A |
| Revenue This Year | $22.67 | $52.14 |
| Revenue Next Year | $15.73 | $4,132.27 |
| P/E Ratio | $131.31 | ★ N/A |
| Revenue Growth | ★ 8.84 | N/A |
| 52 Week Low | $115.57 | $5.59 |
| 52 Week High | $272.60 | $148.83 |
Technical Indicators
Market Signals| Indicator | GWRE | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 38.54 |
| Support Level | $119.27 | $100.33 |
| Resistance Level | $167.31 | $108.00 |
| Average True Range (ATR) | 7.36 | 5.07 |
| MACD | 0.81 | -1.34 |
| Stochastic Oscillator | 69.15 | 0.67 |
Price Performance
Historical ComparisonAbout GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.